Literature DB >> 1798669

Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins.

J Mordenti1, S A Chen, J A Moore, B L Ferraiolo, J D Green.   

Abstract

The clearance and volume of distribution of five human proteins (recombinant CD4, CD4 immunoglobulin G, growth hormone, tissue-plasminogen activator, and relaxin) in humans and laboratory animals were analyzed as a function of body weight using allometric scaling techniques. These proteins cover a 16-fold range of molecular weight (6 to 98 kD), are produced by recombinant or synthetic methods, and may be cleared by different mechanisms. The analyses revealed that the clearance and volume data for each protein were satisfactorily described by an allometric equation (Y = a Wb). The allometric exponent (b) for clearance (ml/min) ranged from 0.65 to 0.84, the allometric exponent for the initial volume of distribution (ml) ranged from 0.83 to 1.05, and the allometric exponent for the volume of distribution at steady state (ml) ranged from 0.84 to 1.02. Exponent values from 0.6 to 0.8 for clearance and 0.8 to 1.0 for volumes are frequently cited for small molecules and are expected based on empirical interspecies relationships. When the preclinical data were analyzed separately, the preclinical allometric relationships were usually predictive of the human results. These findings indicate that the clearance and volume of distribution of select biomacromolecules follow well-defined, size-related physiologic relationships, and preclinical pharmacokinetic studies provide reasonable estimates of human disposition. Employing this methodology during the early phases of drug development may provide a more rational basis for dose selection in the clinical environment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1798669     DOI: 10.1023/a:1015836720294

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  39 in total

1.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.

Authors:  P J Maddon; A G Dalgleish; J S McDougal; P R Clapham; R A Weiss; R Axel
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

2.  T-cell development. Accessories or coreceptors?

Authors:  C A Janeway
Journal:  Nature       Date:  1988-09-15       Impact factor: 49.962

3.  Characterization studies of human tissue-type plasminogen activator produced by recombinant DNA technology.

Authors:  G A Vehar; M W Spellman; B A Keyt; C K Ferguson; R G Keck; R C Chloupek; R Harris; W F Bennett; S E Builder; W S Hancock
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1986

Review 4.  The CD4 antigen: physiological ligand and HIV receptor.

Authors:  Q J Sattentau; R A Weiss
Journal:  Cell       Date:  1988-03-11       Impact factor: 41.582

Review 5.  Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm.

Authors:  H Boxenbaum
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

6.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

Authors: 
Journal:  N Engl J Med       Date:  1985-04-04       Impact factor: 91.245

7.  The pharmacokinetics and pharmacodynamics of a human relaxin in the mouse pubic symphysis bioassay.

Authors:  B L Ferraiolo; M Cronin; C Bakhit; M Roth; M Chestnut; R Lyon
Journal:  Endocrinology       Date:  1989-12       Impact factor: 4.736

8.  [Determination of the antiactivator activity in human and animal blood plasma using tissue plasminogen activator].

Authors:  G V Andreenko; E E Shimonaeva
Journal:  Vopr Med Khim       Date:  1983 Sep-Oct

9.  Dose-dependent pharmacokinetics of recombinant tissue-type plasminogen activator in anesthetized dogs following intravenous infusion.

Authors:  K L Fong; C S Crysler; B A Mico; K E Boyle; G A Kopia; L Kopaciewicz; R K Lynn
Journal:  Drug Metab Dispos       Date:  1988 Mar-Apr       Impact factor: 3.922

10.  Biological properties of a CD4 immunoadhesin.

Authors:  R A Byrn; J Mordenti; C Lucas; D Smith; S A Marsters; J S Johnson; P Cossum; S M Chamow; F M Wurm; T Gregory; J E Groopman; D J Capon
Journal:  Nature       Date:  1990-04-12       Impact factor: 49.962

View more
  49 in total

1.  Allometric scaling of xenobiotic clearance: uncertainty versus universality.

Authors:  T M Hu; W L Hayton
Journal:  AAPS PharmSci       Date:  2001

Review 2.  Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations.

Authors:  T Lavé; P Coassolo; B Reigner
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 3.  The role of pharmacokinetics in the development of biotechnologically derived agents.

Authors:  R J Wills; B L Ferraiolo
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

4.  Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.

Authors:  Patrick M Glassman; Yang Chen; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-12       Impact factor: 2.745

5.  Prediction of drug clearance in humans from laboratory animals based on body surface area.

Authors:  X D Liu; J Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

6.  Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model.

Authors:  Jie Zhao; Yanguang Cao; William J Jusko
Journal:  Pharm Res       Date:  2015-05-05       Impact factor: 4.200

7.  Species difference in the disposition of liposomes among mice, rats, and rabbits: allometric relationship and species dependent hepatic uptake mechanism.

Authors:  H Harashima; S Komatsu; S Kojima; C Yanagi; Y Morioka; M Naito; H Kiwada
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

8.  Engineering challenges for instrumenting and controlling integrated organ-on-chip systems.

Authors:  John P Wikswo; Frank E Block; David E Cliffel; Cody R Goodwin; Christina C Marasco; Dmitry A Markov; David L McLean; John A McLean; Jennifer R McKenzie; Ronald S Reiserer; Philip C Samson; David K Schaffer; Kevin T Seale; Stacy D Sherrod
Journal:  IEEE Trans Biomed Eng       Date:  2013-02-01       Impact factor: 4.538

9.  Interspecies modeling and prediction of human exenatide pharmacokinetics.

Authors:  Ting Chen; Donald E Mager; Leonid Kagan
Journal:  Pharm Res       Date:  2012-11-15       Impact factor: 4.200

10.  Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design.

Authors:  Yulia Vugmeyster; Cynthia Rohde; Mylene Perreault; Ruth E Gimeno; Pratap Singh
Journal:  MAbs       Date:  2013-03-25       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.